InMed announces 1-for-20 reverse share split to regain Nasdaq $1 bid compliance

InMed Pharmaceuticals Inc.

Consolidation ratio 1:20 reduces shares from ~14.36M to ~718k on a non-diluted basis.
Effective with Nasdaq on Nov 14, 2024; adjusted trading begins Nov 15, symbol INM unchanged.
No fractional shares issued; fractions under 0.5 cancelled, otherwise rounded up.
Proportionate adjustment to exercise prices and share counts of options/warrants/convertibles.
Action taken to meet Nasdaq minimum $1.00 bid price continued listing requirement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.